How to offer MOTS-c at your business

Learn what MOTS-c is, where it stands under HHS's interim policy, and how to build a prescription MOTS-c offering.

Glass peptide vial beside a digital healthcare dashboard with pink molecular graphics, representing MOTS-c peptide program infrastructure, pharmacy coordination, and compliance.
Credit: OpenLoop Health

This content is for general informational purposes only. It is not medical or legal advice and does not create a clinician-patient or attorney-client relationship. For guidance on your specific situation, consult a licensed clinician or attorney.

The U.S. The Department of Health and Human Services has eased its enforcement stance on MOTS-c and five other peptides, opening a compounding pathway for this high-interest category. 

On October 28, 2026, HHS released a draft interim enforcement discretion policy stating that the agency does not intend to take enforcement action against state-licensed 503A pharmacies, federal facilities, and licensed physicians that compound these six peptides for individual patients who have a valid prescription, as long as a strict set of conditions is met. 

For operators in health and wellness, it’s a meaningful shift. Patient interest is significant, and MOTS-c previously had no clear compounding pathway.

This guide covers how to offer MOTS-c at your business: what the peptide is, what the policy does and doesn’t allow, and seven steps to build a prescription offering.

What is MOTS-c?

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It was first described in 2015.³

What the research shows

In that original study, MOTS-c treatment in mice was associated with effects on insulin sensitivity and with protection from diet-induced obesity. Published research to date consists largely of cell and animal studies and early human measurements of circulating MOTS-c levels.³ This work does not establish that MOTS-c is safe or effective for any use in people. In its July 2026 briefing materials, FDA reported finding little or no human safety and effectiveness data for MOTS-c.2

Regulatory status

Within HHS’s interim enforcement discretion policy for subcutaneous or intramuscular injectable dosage forms, when the policy’s conditions are met.1 Not FDA-approved. Not on the 503A Bulks List.

Why businesses are adding MOTS-c

Peptides have grown in demand the last few years in parallel with the growing patient interest in more comprehensive, whole health care.

U.S. Google searches for the term “peptides” increased 398% year over year, reflecting growing public interest in the broader industry, and the global peptide therapeutics market is projected to more than double from $140.86 billion in 2025 to $294.58 billion by 2033.

Searches for “MOTS-c peptide” alone increase +650% in the last year (Google Keyword Trends, Nov. 2025 – Nov. 2026) 

MOTS-c now falls within HHS’s interim enforcement discretion policy for 503A compounding. That opens a pathway, when all conditions are met. 

Here’s what operators need to know:

  • It’s a draft, nonbinding policy. HHS is exercising enforcement discretion while the FDA works through formal rulemaking on the 503A Bulks List.
  • MOTS-c is not on the 503A Bulks List and is not Category 1. It’s been recommended for 503A bulk compounding, but formal FDA rulemaking is still required.
  • This does not signify FDA approval or a safe harbor. HHS can narrow or withdraw the policy, in whole or in part, at any time.
  • State requirements still apply. Federal enforcement discretion sits on top of state pharmacy, prescribing, and scope-of-practice rules, not in place of them.

Learn more about the six peptides that now have an interim compounding pathway.

What forms of MOTS-c does the policy cover?

The conditions are specific, and anything outside them falls outside the policy:

  • Form: MOTS-c acetate only. Other salt forms are not covered.
  • Route: Subcutaneous or intramuscular injection only. Oral and other routes are not covered.
  • Formulation: One covered peptide per product. Blends and combinations are not covered.

How to offer MOTS-c at your business

If you want to offer a peptide therapy program that includes MOTS-c, it’s important to prioritize building a clinician-led and patient-first infrastructure that aligns the requirements laid out by the interim policy..

  1. Decide where MOTS-c fits
  2. Choose your delivery model
  3. Build the clinical and regulatory foundation
  4. Vet your pharmacy partner(s)
  5. Standardize the patient journey
  6. Set up the technology
  7. Plan for policy changes

1. Decide where MOTS-c fits

Start with your existing services and patient population. Does a MOTS-c offering fit your focus? Are your patients already asking for it?

Consider three things:

  • Patient demand in your current population
  • Clinical capacity to evaluate and follow patients
  • Alignment with your brand and existing services

2. Choose your care delivery model

MOTS-c can be offered in person, virtually, or through a hybrid model. It also determines certain regulatory restrictions. For instance, multi-state virtual care requires a provider in each state and alignment to that state’s compounding policies. Also, certain states may have different compounding laws and regulations.

Because the policy covers injectable forms only, your model needs a plan for administration:

  • Virtual: Patient self-administration training, with clear written instructions and a fast way to answer questions after the first dose
  • In person or hybrid: Determine whether in-clinic administration is an option and how it fits your scheduling capacity

3. Build the clinical and regulatory foundation

Every MOTS-c patient needs a licensed prescribing clinician and a patient-specific prescription as required by the HHS’s interim enforcement discretion policy and 503A compounding practices. Put the other necessary pieces in place before you enroll your first patient:

  • Documented clinical rationale for each prescription
  • Supervision rules mapped to each state you operate in
  • Standard operating procedures (SOPs) for eligibility, documentation, and follow-up

4. Vet your pharmacy partner

Your pharmacy partner determines whether your product falls within the interim policy. Confirm that every partner:

  • Compounds MOTS-c acetate only, in single-peptide formulations (no single vial combinations)
  • COA documentation: Each bulk substance has a valid, lot-specific COA with testing for identity, purity, potency, and harmful contaminants, including endotoxins, heavy metals, and microbial contamination.
  • Supplier validation: If the pharmacy sources the substance through a repacker, relabeler, or reseller, that intermediary must document validation of the original manufacturer and its COA.
  • Compounding standards: The pharmacy follows applicable USP standards, including USP Chapter 797 for sterile compounding, and maintains appropriate controls to prevent insanitary conditions.
  • Product restrictions: Each compounded product contains only one active pharmaceutical ingredient (API). Single vial combinations, like BPC-157 and TB-500, fall outside the policy.
  • Delivery devices: Any device co-packaged with or containing the compounded product is an FDA 510(k)-cleared syringe.
  • Reporting and labeling: The pharmacy reports compounded products, serious adverse events, and product quality issues to FDA and applicable state authorities. Patient labeling must include the statement “This is a compounded drug product. Not for resale.” and explain how to report adverse events and product quality issues.
  • State requirements: Confirm the pharmacy has the required authority and licensure for the states where it compounds and dispenses, as applicable under state law.

The policy is intended to discourage continued widespread use of certain research-use-only (RUO) peptides from foreign manufacturers that pose safety risks. The practical safeguard is to verify the source, manufacturer registration, and COA rather than rely on a supplier’s research-use-only or other marketing label.

If you’re evaluating potential partners, understanding how 503A compounding pharmacies work can help you ask more informed questions.

5. Standardize the care journey, with clinicians at the center

Map the experience from the first inquiry through follow-up. Patients should understand what the product is, what is known about the research, and what the limitations are.

Build a consistent process for:

  • Intake and clinical evaluation
  • Informed consent 
  • Prescription and dispensing coordination
  • Patient instructions and follow-up
  • Reporting and escalation if a patient experiences a side effect or has a product quality concern

Give patients clear instructions for contacting your team. Define who reviews a report, when the prescribing clinician gets involved, and how serious concerns are escalated.

6. Set up the technology

Your tech stack should connect intake, clinical documentation, patient messaging, lab and pharmacy coordination, and follow-up in one workflow. Ensure all systems and patient data are secure and protected. If you’d rather not assemble that yourself, a white-label platform like OpenLoop® lets you run our pre-built infrastructure under your brand.

7. Plan for policy changes

The draft interim enforcement discretion policy is just that—interim. HHS can revise it at any time. Stay adaptable by building change management into your program from day one:

  • Monitor FDA and HHS updates, including the policy’s Federal Register notice
  • Track discussion around formal 503A Bulks List rulemaking for MOTS-c
  • Have a continuity plan for patients if the policy narrows or ends, including how you’ll communicate changes

By working through these seven steps in order, you’ll have a MOTS-c offering that aligns with your existing services, complies with the policy’s conditions, and can adapt as federal guidance evolves. 

Add peptides to your business with OpenLoop

Building a peptide program takes more than finding a pharmacy. OpenLoop® offers infrastructure to help businesses develop and operate peptide services, including:

  • 503A pharmacy partners where permitted by law
  • Medically reviewed protocols
  • A 50-state clinician network
  • Compliance-aligned infrastructure
  • 24/7/365 patient support

Contact OpenLoop to discuss your business and program needs.

Compounded drugs are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality. The peptides discussed in this article have not been approved by FDA. Compounded preparations require a prescription following an appropriate clinical evaluation, and no prescription is guaranteed. Availability varies based on clinical appropriateness, applicable federal and state laws, pharmacy availability, and other regulatory requirements. Not all peptide therapies are available in all states or through all pharmacies.

References

  1. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Appendix B (substance identity and permitted routes of administration). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  2. U.S. Food and Drug Administration. Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 (introduction and substance-specific briefing documents). https://www.fda.gov/media/193342/download
  3. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID 25738459. https://pubmed.ncbi.nlm.nih.gov/25738459/

Ready to take your brand
to the next level?

Contact us today 
OpenLoop banner ad. Text reads "You focus on your business. We power the care. The short virtual care launch." with a "See how it works" button. A Monday-to-Friday timeline shows a branded site in as little as 24 hours on Monday and program launch on Friday. Fine print notes the timeline is an estimate and actual launch dates may vary by practice.

Explore more related topics